Nexalin Technology, Inc. (NXL)
NXL moved a median of 0.00% 30 minutes after news, and -1.05% by the close. How NXL actually reacts to news — the realized, point-in-time move the market made, measured across 216 labeled events over the last three years with zero look-ahead.
NXL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 198 |
| 30-min | 0.00% | 45% | 211 |
| 60-min | -0.10% | 45% | 213 |
| to close | -1.05% | 38% | 215 |
| Middle 50% of NXL reactions | -2.35% to +2.42% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 216 |
Half of all Nexalin Technology, Inc. news events land between -2.35% and +2.42% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NXL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NXL's baseline. Nothing else.
Recent NXL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form EFFECT Nexalin Technology, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.23% | -3.69% | |
| Form S-1/A Nexalin Technology, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -8.10% | |
| Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing | Press release | GlobeNewswire | -0.47% | -3.29% | |
| Form 8-K Nexalin Technology, Inc. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -0.82% | +4.95% | |
| Form 8-K Nexalin Technology, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -0.82% | +4.95% | |
| Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation | Press release | GlobeNewswire | -14.71% | -14.59% | |
| Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy | Press release | GlobeNewswire | +0.00% | -5.43% | |
| Form 8-K Nexalin Technology, Inc. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.43% | |
| Form S-8 Nexalin Technology, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +4.38% | |
| Form S-1 Nexalin Technology, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -5.60% | |
| Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design o | Press release | GlobeNewswire | -0.66% | -10.96% | |
| Form 8-K Nexalin Technology, Inc. For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | -10.96% | |
| Form 8-K Nexalin Technology, Inc. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +3.29% | +6.17% | |
| Nexalin Technology Announces Reverse Stock Split | Press release | GlobeNewswire | +3.29% | +6.17% | |
| Form 8-K Nexalin Technology, Inc. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -3.65% | -4.45% | |
| Form 8-K Nexalin Technology, Inc. For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.12% | |
| Form 8-K Nexalin Technology, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | +0.00% | |
| Form 10-Q Nexalin Technology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.10% | +1.13% | |
| Form 8-K Nexalin Technology, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | -1.33% | |
| Form 8-K Nexalin Technology, Inc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.00% | |
| Form 8-K Nexalin Technology, Inc. For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | -9.49% | |
| Form ARS Nexalin Technology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.14% | -5.38% | |
| Form DEF 14A Nexalin Technology, Inc. For: Aug 11 | SEC filing · Form DEF | SEC EDGAR | -0.14% | -5.38% | |
| Form PRE 14A Nexalin Technology, Inc. For: Jun 29 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -3.71% | |
| Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform | Press release | GlobeNewswire | +2.75% | +0.03% | |
| Form 8-K Nexalin Technology, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -8.00% | |
| Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life | Press release | GlobeNewswire | +0.70% | -1.06% | |
| Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. | Press release | GlobeNewswire | -11.15% | -9.61% | |
| Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia | Press release | GlobeNewswire | +8.84% | +5.14% | |
| Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury | Press release | GlobeNewswire | +8.49% | +14.00% | |
| Form 8-K Nexalin Technology, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.75% | |
| Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial | Press release | GlobeNewswire | -2.18% | +2.92% | |
| Form 10-Q Nexalin Technology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.03% | +1.09% | |
| Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia | Press release | GlobeNewswire | -0.82% | -10.39% | |
| Form 8-K Nexalin Technology, Inc. For: Apr 17 | SEC filing · Form 8-K | SEC EDGAR | -2.26% | -6.38% | |
| Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | Press release | GlobeNewswire | +8.85% | +7.68% | |
| Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China | Press release | GlobeNewswire | -9.98% | +1.82% | |
| Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 | Press release | GlobeNewswire | +0.97% | +3.94% | |
| Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents | Press release | GlobeNewswire | -4.71% | +6.44% | |
| Form 10-K Nexalin Technology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.07% | -2.10% | |
| Form 8-K Nexalin Technology, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | — | -4.62% | |
| Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market | Press release | GlobeNewswire | +0.80% | -4.31% | |
| Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders | Press release | GlobeNewswire | +0.00% | -2.00% | |
| Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | -2.87% | -0.98% | |
| Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care | Press release | GlobeNewswire | -6.91% | -6.91% | |
| Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation | Press release | GlobeNewswire | +3.13% | +3.73% | |
| Form 8-K Nexalin Technology, Inc. For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | -0.63% | +0.10% | |
| Nexalin Technology Receives Nasdaq Listing Status Notification | Press release | GlobeNewswire | -0.63% | +0.10% | |
| Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD | Press release | GlobeNewswire | +0.69% | +7.30% | |
| Form 8-K Nexalin Technology, Inc. For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -3.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NXL section they belong to.
Where else NXL is measured.
NXL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Nexalin Technology, Inc.'s median reaction calculated?
Every labeled NXL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 216 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of NXL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NXL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.